$IOVA 🗞️WCLC 2026 is on and we are already hearing some news from ongoing clinical trials on NSCLC.
Below, we can see how Merck-Gilead’s EVOKE-03 did not meet the primary end point thanks to Dr. Stephen (and bavariaron on StockTwits).
So far we see some promising early data as